國家衛生研究院 NHRI:Item 3990099045/15592

NHRI > National Center for Geriatrics and Welfare Research > Chih-Cheng Hsu > Periodical Articles > Item 3990099045/15592

Please use this identifier to cite or link to this item: http://ir.nhri.org.tw/handle/3990099045/15592

Title:	Effects of glucagon-like peptide-1 receptor agonists on liver-related and cardiovascular mortality in patients with type 2 diabetes
Authors:	Yen, FS;Hou, MC;Wei, JCC;Shih, YH;Hwu, CM;Hsu, CC
Contributors:	Institute of Population Health Sciences;National Center for Geriatrics and Welfare Research
Abstract:	BackgroundPatients with type 2 diabetes (T2D) tend to have nonalcoholic fatty liver disease (NAFLD) with poorer prognosis. We performed this research to compare the risks of cardiovascular diseases, cirrhosis, liver-related mortality, and cardiovascular mortality between glucagon-like peptide-1 receptor agonist (GLP-1 RA) use and no-use in patients with T2D without viral hepatitis.MethodsFrom January 1, 2008, to December 31, 2018, we used propensity-score matching to identify 31,183 pairs of GLP-1 RA users and nonusers from Taiwan's National Health Insurance Research Database. Multivariable-adjusted Cox proportional hazards models were used to examine the outcomes between the study and control groups.ResultsThe median (Q1, Q3) follow-up time for GLP-1 RA users and nonusers were 2.19 (1.35, 3.52) and 2.14 (1.19, 3.68) years, respectively. The all-cause mortality incidence rate was 5.67 and 13.06 per 1000 person-years for GLP-1 RA users and nonusers, respectively. Multivariable-adjusted analysis showed that GLP-1 RA use had significantly lower risks of all-cause mortality (aHR 0.48, 95%CI 0.43-0.53), cardiovascular events (aHR 0.92, 95%CI 0.86-0.99), cardiovascular death (aHR 0.57, 95%CI 0.45-0.72), and liver-related death (aHR 0.32, 95%CI 0.13-0.75). However, there was no significant difference in the risk of liver cirrhosis development, hepatic failure, and hepatocellular carcinoma compared to GLP-1 RA no-use.ConclusionsThis nationwide cohort study showed that GLP-1 RA use was associated with a significantly lower risk of all-cause mortality, cardiovascular events, and cardiovascular death in patients with T2D among Taiwan population. More prospective studies are warranted to verify our results.
Date:	2024-01-04
Relation:	BMC Medicine. 2024 Jan 04;22:Article number 8.
Link to:	http://dx.doi.org/10.1186/s12916-023-03228-4
JIF/Ranking 2023:	http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=1741-7015&DestApp=IC2JCR
Cited Times(Scopus):	https://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85181248319
Appears in Collections:	[Chih-Cheng Hsu] Periodical Articles [Chih-Cheng Hsu] Periodical Articles

Files in This Item:

File	Description	Size	Format
ISI001136292700001.pdf		860Kb	Adobe PDF	190	View/Open

Loading...